Views and missives from the frontier

October 25, 2019

Richard Young, Ph.D., Founder of CAMP4 Therapeutics, Elected to National Academy of Medicine


Cambridge, Mass., Oct. 25, 2019 – CAMP4 Therapeutics, a biotechnology company unraveling transcriptional machinery and the network of signaling pathways to accelerate drug discovery and development across therapeutic areas, announced that Richard Young, Ph.D., one of the company’s founders, has been elected to the National Academy of Medicine (NAM). Dr. Young, a Member of the Whitehead Institute and Professor of Biology at the Massachusetts Institute of Technology (MIT), was one of 90 regular members and 10 international members elected to NAM earlier this week. Election to NAM is considered one of the highest honors in the fields of health and medicine, recognizing individuals who have made major contributions to the advancement of the medical sciences, health care and public health. Dr. Young was elected to the National Academy of Sciences in 2012 as well.

Dr. Young’s research focuses on mapping the regulatory circuitry that controls cell state and differentiation—using experimental and computational technologies to determine how signaling pathways, transcription factors, chromatin regulators, and small RNAs control gene expression.

CAMP4 was founded based on the seminal discoveries made by Dr. Young, along with Leonard Zon, M.D., Grousbeck Professor of Pediatric Medicine at Harvard Medical School, Investigator at Howard Hughes Medical Institute, and Director of the Stem Cell Program at Boston Children’s Hospital. 

Based on Drs. Young and Zon’s discoveries, CAMP4 has built its proprietary Gene Circuitry Platform™, with which it is pioneering a systematic and scalable approach to discover new, druggable targets to control gene expression to treat diseases across all therapeutic areas.

“On behalf of the entire CAMP4 team, I want to congratulate Rick on this tremendous and well-deserved honor,” said Josh Mandel-Brehm, Chief Executive Officer of CAMP4. “In addition to all of his remarkable scientific accomplishments that have the potential to impact people’s lives around the world, and the numerous resulting accolades bestowed on him, I am continually struck by Rick’s incredibly humility and humanity. We are grateful to have the opportunity to work with and advance Rick’s science and vision.”

Dr. Young received his Ph.D. in Molecular Biophysics and Biochemistry at Yale University, conducted postdoctoral research at Stanford University and joined Whitehead Institute and MIT in 1984. He has served as an advisor to the National Institutes of Health, the World Health Organization, the Vatican and numerous scientific societies and journals. Dr. Young has founded and advised companies in the biotechnology and pharmaceutical industry and is currently a member of the Board of Directors of CAMP4, Syros Pharmaceuticals and Omega Therapeutics. His honors include Membership in the National Academy of Sciences, the Chiron Corporation Biotechnology Research Award, Yale’s Wilbur Cross Medal, and in 2006 Scientific American recognized him as one of the top 50 leaders in science, technology and business.

The National Academy of Medicine, established in 1970 as the Institute of Medicine, is an independent organization of eminent professionals from diverse fields including health and medicine; the natural, social, and behavioral sciences; and beyond. It serves alongside the National Academy of Sciences and the National Academy of Engineering as an adviser to the nation and the international community. Through its domestic and global initiatives, the NAM works to address critical issues in health, medicine, and related policy and inspire positive action across sectors. The NAM collaborates closely with its peer academies and other divisions within the National Academies of Sciences, Engineering, and Medicine.

View the Whitehead Institute’s statement on Dr. Young’s election to NAM.

About CAMP4 Therapeutics

At CAMP4 Therapeutics, we are revolutionizing drug discovery and development to be faster, smarter and better. With our Gene Circuitry Platform™, we have discovered how to dial up or dial down the expression of any gene. Using the foundational insights enabled by our platform, we are pioneering a systematic and scalable approach to discover new, druggable targets to control gene expression to treat diseases across all therapeutic areas. This approach involves creating tissue-specific Gene Circuitry Maps™ that comprehensively reveal the transcriptional machinery and its connected network of signaling pathways governing gene expression. Each map serves as its own therapeutic area discovery engine, revealing dozens, sometimes even hundreds of disease-solving opportunities. Our goal is to decipher the transcriptional machinery and signaling networks controlling gene expression for all cell types central to disease, ultimately delivering druggable targets for a multitude of undruggable diseases. Our vision is to create a world where a treatment for every disease is possible. Learn more about us at

Media Contact:

Lindy Devereux
Scient PR